Eli Lilly and Co., already struggling to overcome its largest financial challenges in decades, got another dose of bad news late Thursday when a federal judge ruled that a key patent on Strattera, its drug for attention-deficit disorders, was invalid.
The ruling could allow generic competitors to launch low-cost competing versions of Strattera within months, cutting sharply into Lilly's sales. Last year, Strattera rang up $609.4 million worldwide, up 5 percent from the year before.
via indystar.com
No comments:
Post a Comment